Blood Sample May Establish Patient Radiosensitivity
By MedImaging International staff writers Posted on 25 Oct 2017 |
A new study suggests that flow cytometry analysis can be used to measure a patient’s DNA sensitivity to radiation and chemotherapy treatments.
Under development at Sahlgrenska Academy (Göteborg, Sweden), the flow-cytometry-based cell division (CD) assay uses the thymidine analogue 5-ethynyl-2’-deoxyuridine (EdU) to measure the proliferative ability of cells after DNA damaging treatment. In validation studies, the CD assay measured sensitivity to radiation of human skin fibroblasts with a correlation similar to standard clonogenic survival assay, and in a relatively short time frame. Using easily sampled peripheral blood lymphocytes, the CD assay was able to identify variation in intrinsic sensitivity to radiation, and also detected increased sensitivity in patients with DNA repair defects.
As exposure to ionizing radiation generates free radicals that carry out most part of the toxic effects, the researchers conducted a second study to examine if pretreating cells with an Nrf2 transcription factor activator, which regulates the cellular antioxidant system, could influence sensitivity to radiation. The results showed that repeated pretreatment of cells with Nrf2 activators, isothiocyanate sulforaphane, or synthetic triterpenoid bardoxolone methyl can enhance cytoprotection. The study was presented as a PhD dissertation in September 2017.
“The main idea behind our method is to measure patient sensitivity during the planning process for the cancer treatment and to identify which patients are extremely sensitive,” study dissertation presenter Sherin Mathew, PhD. “It will be better to have this knowledge about the patients; as it stands right now we don't know how each patient will respond when the radiation or chemotherapy is administered. The idea is that it will be possible to test sensitivity and prevent extremely sensitive patients from having serious side effects.”
Flow cytometry is a biophysical technology employed in cell counting, cell sorting, biomarker detection, and protein engineering by suspending cells in a stream of fluid and passing them through an electronic laser or impedance-based detection apparatus that allows simultaneous multiparametric analysis of the physical and chemical characteristics of up to thousands of particles per second. Flow cytometry is routinely used in the diagnosis of health disorders, especially blood cancers, but has other applications in basic research, clinical practice, and clinical trials.
Related Links:
Sahlgrenska Academy
Under development at Sahlgrenska Academy (Göteborg, Sweden), the flow-cytometry-based cell division (CD) assay uses the thymidine analogue 5-ethynyl-2’-deoxyuridine (EdU) to measure the proliferative ability of cells after DNA damaging treatment. In validation studies, the CD assay measured sensitivity to radiation of human skin fibroblasts with a correlation similar to standard clonogenic survival assay, and in a relatively short time frame. Using easily sampled peripheral blood lymphocytes, the CD assay was able to identify variation in intrinsic sensitivity to radiation, and also detected increased sensitivity in patients with DNA repair defects.
As exposure to ionizing radiation generates free radicals that carry out most part of the toxic effects, the researchers conducted a second study to examine if pretreating cells with an Nrf2 transcription factor activator, which regulates the cellular antioxidant system, could influence sensitivity to radiation. The results showed that repeated pretreatment of cells with Nrf2 activators, isothiocyanate sulforaphane, or synthetic triterpenoid bardoxolone methyl can enhance cytoprotection. The study was presented as a PhD dissertation in September 2017.
“The main idea behind our method is to measure patient sensitivity during the planning process for the cancer treatment and to identify which patients are extremely sensitive,” study dissertation presenter Sherin Mathew, PhD. “It will be better to have this knowledge about the patients; as it stands right now we don't know how each patient will respond when the radiation or chemotherapy is administered. The idea is that it will be possible to test sensitivity and prevent extremely sensitive patients from having serious side effects.”
Flow cytometry is a biophysical technology employed in cell counting, cell sorting, biomarker detection, and protein engineering by suspending cells in a stream of fluid and passing them through an electronic laser or impedance-based detection apparatus that allows simultaneous multiparametric analysis of the physical and chemical characteristics of up to thousands of particles per second. Flow cytometry is routinely used in the diagnosis of health disorders, especially blood cancers, but has other applications in basic research, clinical practice, and clinical trials.
Related Links:
Sahlgrenska Academy
Latest Nuclear Medicine News
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure
- New PET Radiotracer Aids Early, Noninvasive Detection of Inflammatory Bowel Disease
- Combining Amino Acid PET and MRI Imaging to Help Treat Aggressive Brain Tumors